A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib.

Xin Huang Guiying Zhang Shuaihantian Luo

Published in: The Journal of dermatological treatment (2024)

Conclusions: Upadacitinib may be a potential drug candidate in patients with treatment-resistant ADM, especially in cases with refractory cutaneous conditions.

Keyphrases

signaling pathway
interstitial lung disease
systemic sclerosis
breast cancer cells
disease activity
idiopathic pulmonary fibrosis
emergency department
human health
risk assessment
drug induced